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Abstract
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for
(re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A
panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to
formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it.
Methods Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response
and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a
nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus.
Results PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response,
patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA
PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to
treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial
response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic
disease deserve special consideration.
Conclusions Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for inter-
pretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve
special consideration.
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Introduction
Prostate-specific membrane antigen (PSMA) positron emis-
sion tomography (PET)/computed tomography (CT) is being
used more frequently for prostate cancer (PCa) staging and for
localization of recurrent disease [1].
International guidelines, including the guideline of the
European Association for Urology (EAU) [2], have incorpo-
rated PSMA PET/CT and provide recommendation on its ap-
propriate use. It is the consensus imaging modality in patients
with rising PSA after radical treatment to confirm a diagnosis
of oligorecurrent (metachronous) oligometastatic PCa [3]. In
other clinical situations, such as PSA persistence after radical
treatment, PSMA PET/CT is also recommended [2], while for
initial staging of high-risk patients, the ultimate role of PSMA
PET/CT is still debated. Themost recent results of prospective
trials are very promising [4, 5].
There are procedure guidelines for performing PSMA
PET/CT endorsed by European Association of Nuclear
Medicine (EANM) [1]. PSMA PET/CT is considered a poten-
tially useful tool for evaluating responses to therapy, but there
is lack of data regarding criteria to be used for evaluating
PSMA PET/CT findings in relation to therapy response as-
sessment [2, 4]. In recognition of the growing importance of
PSMA radiopharmaceuticals in the diagnosis and treatment of
patients with PCa, the EAU in collaboration with EANM re-
cruited a panel of international experts in PCa within the fields
of nuclear medicine, radiology, and urology, who met on
February 21, 2020, in Amsterdam, The Netherlands, for an
European consensus panel to formulate criteria for PSMA
PET/CT-based response and progression in patients treated
for metastatic PCa and when to use it. The main output of this
meeting was the development of sets of consensus statements
concerning PSMAPET/CT criteria for response assessment in
various clinical scenarios for patients with metastatic PCa, and
these are presented here.
Materials and methods
A modified nominal group technique was used to reach con-
sensus statements on PSMA PET/CT response assessment
criteria [6, 7]. Ten weeks prior to meeting, each panelist re-
ceived thematic topics concerning PSMA PET/CT response
assessment along with relevant literature suggested by the
panelists. The panelists (Stefano Fanti, Karolien Goffin,
Boris Hadaschik, Ken Herrmann, Tobias Maurer, Daniela
Oprea-Lager, Wim JG Oyen, Olivier Rouvière, and Anders
Bjartell), all authors of this paper, are PCa experts in nuclear
medicine (five panelists), radiology (one panelist), or urology
(three panelists). A one-day meeting was held, where the the-
matic topics were again presented. The panelists were subse-
quently divided into two groups, each containing a balance of
experts in the aforementioned specialties, to separately discuss
these thematic topics in greater detail and develop statements
related to the use of PSMA PET/CT. The breakout groups
then reconvened, discussed all statements written by each
subgroup, and created a combined list of statements organized
under thematic topics.
For the scope of the present project, PSMA PET/CT refers
to PET/CT imaging performed with PSMA-targeting
radioligands (e.g., [68Ga]Ga-PSMA-11, [18F]F-PSMA-1007,
[18F]DCFPyL).
Each statement was singular and phrased so that panel
members could agree or disagree with it. The resulting state-
ments were uploaded to an online voting tool, and the panel-
ists voted anonymously online [8]. Panelists voted on a nine-
point scale, ranging from strongly disagree (1) to strongly
agree (9) (i.e., 1–3 disagree, 4–6 uncertain, 7–9 agree). The
results of the vote on each statement were conveyed to partic-
ipants immediately after voting.
The statistical analysis of the voting focused on the level of
agreement (median score) with each statement and whether
there was consensus (dispersion of scores around the median).
This followed the methods proposed by the research and de-
velopment project (RAND)/University of California, Los
Angeles (UCLA) Appropriateness Method which has been
shown to be robust for smaller panels and can be used in
panels of any size [9]. For each statement, first the median
score was calculated, then the 30th and 70th percentiles were
calculated, which constitute the interpercentile range (IPR).
The IPR was used to calculate the interpercentile range adjust-
ed for symmetry (IPRAS), which is calculated using the for-
mula: IPRAS = 2.35 + (asymmetry index [AI] * 1.5), where
the AI is defined as the absolute difference between the central
point of the IPR and 5 (i.e., the central point on the 1–9 scale).
If the IPR < IPRAS, then this indicates there is no extreme
dispersion of scores (i.e., there is “consensus”).
The median agreement score (MAS) was used to determine
the level of agreement: a MAS in the 1–3 range indicated the
panel disagreed with the statement, a MAS in the 4–6 range
indicated the panel were uncertain, and a MAS in the 7–9
range indicated the panel agreed with the statement. Then,
the IPRAS was used to assess consensus. For a statement to
be considered to have agreement and consensus, two condi-
tions had to be met: a median score in the 7–9 category and an
IPRAS < IPR.
Results
Within the scope of each thematic topic, statements were de-
veloped by the panelists during the one-day meeting
concerning how to interpret PSMA PET/CT to define re-
sponse and progression in patients treated for metastatic PCa
and when to use it. These thematic topics and statements along
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with the corresponding MAS, IPR, and IPRAS from the vot-
ing are reported in Table 1. Briefly, the statements covered the
best timing for performing PSMA PET/CT, the criteria that
should be used to evaluate the PSMA PET/CT response, the
patients who could benefit from such evaluation from a clin-
ical perspective, and how the various PSMA-targeting PET
tracers should be handled.
Other relevant thematic topics were also addressed with
statements: Available real-world data and/or trial data should
be analyzed for response assessment with PSMA PET/CT
before designing future prospective trials; Criteria for treat-
ment assessment should be evaluated in test-retest trials to
assess normal variability in the measurement. In every in-
stance, the MAS fell in the 7–9 category and IPR as lower
than IPRAS, so there was “agreement” and “consensus.”
As an antecedent to the discussion of the thematic topics,
the panelists considered the utility and impact of PSMA PET/
CT in PCa and developed four statements and reached con-
sensus on all four.
• PSMA PET/CT is currently the most sensitive imaging
staging technique for depicting metastases at any stage of
the disease. MAS = 8 (IPR = 1; IPRAS = 7.6).
• Use of PSMA PET/CT will cause stage migration, which
is a problem for clinical decision-making. MAS = 8
(IPR = 0; IPRAS = 6.85).
• PSMA PET/CT should be used as imaging tool at bio-
chemical recurrence. MAS = 9 (IPR = 0; IPRAS = 8.35).
• PSMA PET/CT should not be used in low-risk disease.
MAS = 9 (IPR = 0; IPRAS = 8.35).
Discussion
All consensus statements were developed following the
European Society for Radiotherapy and Oncology (ESRO)
and European Organisation for Research and Treatment of
Cancer (EORTC) consensus recommendations for classifica-
tion of oligometastatic disease [10].
General statements
Regarding the use of PSMAPET/CT for assessing response to
therapy, it was confirmed that such an approach should be
used only if a change of clinical management is expected from
the results (statements 1.2 and 2.4) as already emphasized in
EAUGuidelines [2]. Thus, in case of good PSA response after
salvage treatment, there is no indication for performing PSMA
PET/CT (statement 1.4); also, in case of late-stage disease
where no further therapies can be initiated or hormone sensi-
tive PCawith favorable PSA response under systemic therapy,
there is no role for PSMA PET/CT (statements 1.5 and 1.6).
Asking whether PSMA PET/CT can be used before, after,
and during treatment is an important question, because there
are, for example, concerns regarding how to interpret uptake
of tracer especially in hormone-naive patients starting andro-
gen deprivation therapy (ADT) [11]. Consensus was reached
on the statement that in principle, PSMA PET/CT can be used
before and after any local and systemic treatment in patients
with metastatic disease (including N1 disease). PSMA PET/
CT is actually the most sensitive technique to detect metasta-
ses, and thus, it is likely that the prognosis of M0 and M+
patients based on PSMA PET/CT will be changed, as com-
pared to the prognosis of M0 and M+ patients based on stan-
dard work up (CT and bone scan). Nonetheless, in the absence
of clinical trials assessing the prognosis of patients with me-
tastases detected only by PSMA, it remains unclear whether
PSMA PET/CT should be widely used in high-risk patients.
The panel is well aware that the proposed criteria are based
on practical experience and authors’ opinions; indeed, there is
very little data to ultimately support some of the statements
that are made. Nonetheless, it is clear that some baseline
criteria are proposed to be used for future studies and applied
for clinical scenarios that are already happening. With expect-
ed publication of more data from prospective studies, it will
hopefully be possible to refine the statements proposed here,
possibly with future further consensus events to be held for
review of datasets with outcome measures. Once the criteria
have been evaluated in clinical trials, they could surely be
improved.
Timing for PSMA PET/CT
With respect to the best timing for performing PSMA PET/
CT, some evident prerequisites were confirmed, such as that
in case of primary PCa negative on PSMA PET/CT, further
imaging with PSMA PET/CT is generally not adequate (state-
ment 2.1), and if used for response assessment, baseline
PSMA PET/CT should be performed before the start of treat-
ment (statement 2.2).
The panelists agreed that potential flare observed in a
PSMA scan following initiation of ADT is an early event,
and misinterpretation can be avoided by performing the scan
not earlier than 3 months after the start of ADT (see also
statement 2.3). Data concerning the flare phenomenon ob-
served with ADT and second-generation anti-androgen thera-
py are limited and not unequivocal [12–15]. The correlation
between androgen signaling and PSMA expression seems to
be quite complex and requires more study before practice-
defining conclusions can be drawn. Nonetheless, the panelists,
based on their practical experience, suggested 3 months as the
minimal timing for performing PSMA PET/CT after initiation
of hormonal intervention. A prospective study has shown that
androgen deprivation therapy could impact the timing for
PSMA PET/CT [16]. The study included 15 men, eight pa-
tients with metastatic hormone sensitive PCa treated with lu-
teinizing hormone-releasing hormone and bicalutamide and
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Table 1 Consensus statements on PSMA PET/CT response assessment criteria along with their respective median agreement scores (MAS),
interpercentile ranges (IPR), and interpercentile ranges adjusted for symmetry (IPRAS)
Thematic topic and corresponding statement
Statement MAS IPR IPRAS
1. Can PSMA PET/CT be used before and after any treatment?
1.1 In principal, PSMA PET/CT can be used before and after any local and systemic treatment in
patients at risk of having metastatic disease (including N1 disease).
8 1 7.6
1.2 PSMA PET/CT should not be used if no change of clinical management is expected. 9 0 8.35
1.3 PSMA PET/CT should not be used if local disease within the prostate is expected. 8 1 7.6
1.4 After salvage treatment of oligometastatic PCa with curative intent, if PSA indicates complete
response, PSMA PET/CT is to be avoided as an assessment tool.
9 0.6 7.9
1.5 Routine use of PSMA PET/CT should not be used in patients with hormone sensitive PCa
and PSA response under systemic therapy.
8 0.6 7.3
1.6 Routine use of PSMA PET/CT should not be used in patients with late-stage disease where no
further therapies can be initiated.
7 0 5.35
2. What is the best timing for performing PSMA PET/CT?
2.1 In cases where the primary PCa is negative on PSMA PET/CT, further staging with PSMA
PET/CT is generally not adequate, and other imaging should be performed.
9 0 8.35
2.2 If used for response assessment, then a PSMA PET/CT should be performed before the start
of treatment (i.e., baseline PSMA PET/CT).
9 0 8.35
2.3 PSMA PET/CT should not be performed within three months after initiation of systemic therapy
in hormone sensitive PCa.
9 1 7.6
2.4 PSMA PET/CT should not be performed for routine follow-up if management of the patient
is unlikely to change.
9 0.6 7.9
3. Which PET criteria should be used to evaluate the PSMA response?
3.1 For clinicians, PSMA PET/CT should always be accompanied by evaluation of clinical and laboratory data. 9 0 8.35
3.2 For imaging specialists, only treatment response criteria for PSMA PET/CT are needed
(not taking other parameters into account (e.g. PSA, etc.).
9 1 7.6
3.3 Ideally, PSMA PET/CT criteria should categorize patients as responders or non-responders. 9 0 8.35
3.4 Categories of responders should include patients with stable disease and partial and complete response
on PSMA PET/CT imaging; non-responders should include patients with progressive disease
on PSMA PET/CT.
8 1.2 6.85
3.5 In early recurrent PCa, appearance of any new lesion with high suspicion should be regarded as progressive disease. 8 1 7.6
3.6 In polymetastatic PCa, increase of uptake or tumor volume > 30% is defined as progressive disease. 8 1 7.6
3.7 In polymetastatic PCa, appearance of two or more new lesions should not be regarded as progressive
disease, if total tumor volume or uptake does not increase > 30%.
9 1 7.6
3.8 PCWG3-criteria for evaluation of bone scintigraphy should not necessarily be used for PSMA PET/CT evaluation. 9 0.6 7.9
3.9 Complete response: complete disappearance of any lesion with tracer uptake; partial response:
reduction of uptake and tumor volume by > 30%; SD: change of uptake and tumor volume ± ≤ 30%
and no new lesions; progressive disease: appearance of two or more new lesions and/or increase of
uptake or tumor PET volume > 30%.
9 0.6 7.3
4. Which patients could benefit from PSMA response assessment from a clinical perspective (other than those
for whom a treatment change will have a significant impact on outcome)?
4.1 PSMA PET/CT response assessment should be evaluated in the context of clinical trials. 9 0 8.35
4.2 In clinical practice, PSMA PET/CT response assessment may be performed in patients with inconsistent
laboratory findings and/or clinical course of the disease if change of management is considered.
9 0 8.35
5. How should the various PET tracers be handled?
5.1 Different 68Ga and 18F radiolabeled PSMA tracers (e.g., [68Ga]Ga-PSMA-11, [18F]PSMA-1007, and
[18F]DCFPyL) show similar performance even if there is lack of comparative data.
8 1 7.6
5.2 For response assessment the same PSMA PET tracers should be used. 9 0 8.35
5.3 Quality assurance is mandatory either for radiotracer production and image acquisition and
should include EARL-harmonized protocols (scanner, reconstruction algorithms) regarding
dosage, time of acquisition and quantification should be done using validated software.
9 0 8.35
6. Other relevant statements
6.1 Available real-world data and/or trial data should be analyzed for response assessment with
PSMA PET/CT before designing future prospective trials.
9 0 8.35
6.2 Criteria for treatment assessment should be evaluated in test-retest trials to assess normal variability
in the measurement.
9 1 7.6
EARL, European Association of Nuclear Medicine Research Ltd.; IPR, interpercentile range; IPRAS, interpercentile range adjusted for symmetry;MAS,
median agreement score; PCa, prostate cancer
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seven patients with castration resistant PCa treated with
enzalutamide or abiraterone, and showed that at 9 days post
treatment, [68Ga]Ga-PSMA-11 PET/CT SUVmax decreased
in the hormone-sensitive patients (median 30% (interquartile
range 5–61) but increased in the castration-resistant PCa (me-
dian 45% (interquartile range 12.7–66)).
Criteria for interpretation of PSMA PET/CT
Criteria to be used to evaluate PSMA response were thorough-
ly discussed and addressed. Indeed, molecular response
criteria have been proposed as better than morphological
criteria in patients with metastatic castration resistant PCa
[17], but the precise criteria to be used have not been identi-
fied. There are no clear definitions for oligometastatic and
polymetastatic disease, so, in the context of this report, pro-
gression was defined in order to start creating guidance on
how to use PSMA PET/CT. In general, there is confidence
in drawing conclusions in cases with complete response as
well as for detecting clear progression of disease and scoring
of new lesions [18–20], but uncertainty remains for everything
in between.
The panelists agreed that PSMA PET/CT criteria should
categorize patients as responders or non-responders (statement
3.3) for both, clinical use and trial incorporation. Given the
nature of PCa, it was agreed that categories of responders
should include patients with stable disease, partial response,
and complete response on PSMA PET/CT imaging; non-
responders should include patients with progressive disease
on PSMA PET/CT (statement 3.3). In this light, the consensus
statements were written with progression defined as a 30%
increase of tumor burden, and this is in line with other studies
andmodified PET response criteria in solid tumors (PERCIST)
[21–23]. In general, the panel agreed on a definition of PSMA
response as Complete in case of disappearance of any lesion
with tracer uptake; Partial as reduction of uptake and tumor
PET volume by > 30%; Stable as change of uptake and tumor
PET volume ± ≤ 30% without evidence of new lesions;
Progression as appearance of > 2 new lesions or increase of
uptake or tumor PET volume >= 30% (statement 3.9).
While these criteria are ready to be used in most situations,
and should be evaluated in future studies, some specific clin-
ical scenarios deserve special consideration. The definition of
progression indicated by the panel is largely in line with the
proposal of PSMA PET progression [18], largely based on the
appearance of ≥ 2 new lesions, which is adequate in many
cases. Nonetheless, the panelists agreed that in early recurrent
PCa, appearance of any new lesion with high suspicion should
be regarded as progressive disease (statement 3.5). The ratio-
nale was to maximize the sensitivity of the approach in such
settings, where additional local therapies may still be pro-
posed. Conversely, in polymetastatic PCa, increase of uptake
or tumor PET volume > 30% was regarded as progression;
appearance of two or more new lesions should not be neces-
sarily regarded as progressive disease, if total tumor PET vol-
ume or uptake does not increase > 30% (statements 3.6 and
3.7). For the purpose of this project, the definition of a new
lesion is based on the appearance of a new focal area of PSMA
uptake at PET, with or without CT change. Disease progres-
sion should not be based solely on PET/CT. The rationale here
was to avoid misinterpretation of progressive disease in case
of an overall good response of known lesions to systemic
therapy with only appearance of a few minor lesions.
Indeed, it would be a mistake to switch an active treatment
too early in polymetastatic situations.
Semi-quantitative evaluation of radiolabeled PSMA PET/
CT scans could be very useful when assessing response to
treatment. Standardized uptake value (SUV) is the most com-
monly used semi-quantitative parameter, providing a measure
of radiotracer uptake. The main recommendation for using
SUV parameters, (SUVmax, SUVmean, or SUVpeak) is to
optimize reproducibility by limiting all variation factors (qual-
ity of injection, uptake time, type of scanner, reconstruction
algorithm, and others), namely to rigorously harmonize pro-
cedures and parameters in all scans. Volumetric PETmeasure-
ments (so called tumor burden values) based on available
software packages can partly overcome such problems [24,
25], since they account for less variations across patients and
are better reproducible. However, these parameters are still not
widely used in clinical practice because they are technically
demanding. Tools for quantitative estimation of the total tu-
mor burden are under development, and these could reduce
current problems with interobserver variability and low repro-
ducibility with manual interpretation of images.
The use of uptake thresholds based on PERCIST could not
be supported by the literature, because these have only been
validated for FDG PET. Nonetheless, the panelists agreed that
a threshold should be arbitrarily chosen as baseline for future
studies; furthermore, it should be at least wider than repeat-
ability coefficients (published only for the PSMA-targeted
agent DCFPyL) and could be modified in the future to hope-
fully arrive at the appropriate cut-offs for tumor response [25].
Need for standard interpretation of scans
Quality standards for interpretation of PSMA PET/CT scans
are needed. Visual, qualitative assessment of the attenuated
and non-attenuated PET images is the basis of any PET study
interpretation. The major concern regarding this assessment is
the significant inter- and intra-observer variability of PET im-
age interpretation. Therefore, quality standards for interpreta-
tion of PSMA PET/CT scans are needed. Yet, the report from
the nuclear medicine physician needs to adhere to quality
standards, as recently proposed in the E-PSMA: the EANM
standardized reporting guidelines for PSMA PET/CT. The
quality of the procedure itself is standardized using existing
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procedures guidelines to obtain high-quality imaging [1], and
the same applies to quantification software.
Different PSMA tracers, including [68Ga]Ga-PSMA-11
and [18F]F-labeled PSMA-1007 and [18F]DCFPyL tracers,
are supposed to perform similarly, even if there is lack of
comparative data [26]. For response assessment, it is evident
that the same PSMA PET tracers should be used for baseline
and subsequent imaging. Quality assurance is mandatory for
both radiotracer production and image acquisition.
Limit of the methodology
There was consensus for every statement, and this is undoubt-
edly related to the fact that the panel mostly created the state-
ments on the meeting day and discussed them in depth before
voting. In-group bias is therefore a potential limitation, but the
panel were sampled from the two most directly relevant pro-
fessional societies (EANM and EAU) and these individuals
represent expertise on this topic. Furthermore, voting was
anonymous, so had any participant disagreed with the state-
ments, there was a channel to express disagreement.
The panelists refrained from evaluating response to some
particular therapies due to lack of data. As previously men-
tioned, the proposed criteria were mainly based on practical
experience. Lutetium PSMA, due to its theranostic nature, is
the only treatment where PSMA PET/CT has been used more
frequently to evaluate response to therapy [27, 28]. For this
indication, PSMA PET/CT is mandatory for establishing the
suitability of treatment, and prognostic information can be
derived from baseline PSMA PET/CT [29]. It is also possible,
that PSMA PET/CT could be used to describe duration of
response and decide the frequency of treatment.
Perspective
Available real-world data and/or trial data should be analyzed
for response assessment with PSMA PET/CT before design-
ing future prospective trials. Furthermore, criteria for treat-
ment assessment should be evaluated in test-retest trials to
assess normal variability in the measurement.
Conclusions
PSMA PET/CT is currently the most rapidly growing imaging
technique in PCa, but its adoption should be adequately sup-
ported by indication for appropriate use and precise criteria for
interpretation. PSMA PET/CT holds great potential in several
clinical situations. Use of PSMA PET/CT should not be con-
sidered, if no change of clinical management is expected.
For evaluation of response to treatment, PSMA PET/CT
can be used before and after any local and systemic treatment
in patients with metastatic disease. However, it should not be
performed within 3 months after initiation of systemic therapy
in hormone sensitive PCa.
Ideally, PSMA PET/CT criteria should categorize patients
as responders or non-responders: categories of responders in-
clude patients with stable disease, partial response, and com-
plete response on PSMA PET/CT imaging. Specific clinical
scenarios such as oligometastatic or polymetastatic disease
deserve special consideration. The use of PSMA PET/CT re-
sponse assessment should be implemented and evaluated in
the context of clinical trials.
EAU and EANM endorse and promote high-quality stan-
dards in performing and reporting PSMA PET/CT scans.
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